Indeed, PDL1-targeted α41BB enhanced CD19-Bite induced T-cell activation (Figure 7) but also T-cell anti-tumor cell activity against genetically engineered tumor cells expressing membrane-bound αCD3 (Figure 6). This evidence concerns the gene CD19 and neoplasm.